ARROWHEAD PHARMACEUTICALS, INC. Investment Income, Amortization of Premium
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Investment Income, Amortization of Premium of $231.90 thousand for the 12-month period ending 2016-09-30, per its 10-K filed 2016-12-14.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeAmortizationOfPremium · last filed 2017-02-06
- ARROWHEAD PHARMACEUTICALS, INC. investment income, amortization of premium for the quarter ending 2016-09-30 was $30.56K, a 81.53% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. investment income, amortization of premium for the quarter ending 2016-06-30 was $21.89K, a 92.09% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. investment income, amortization of premium for the quarter ending 2016-03-31 was $71.06K, a 77.84% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. investment income, amortization of premium for the quarter ending 2015-12-31 was $108.40K, a 68.82% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. investment income, amortization of premium for fiscal 2016 was $231.90K, a 79.12% decline from fiscal 2015.
- ARROWHEAD PHARMACEUTICALS, INC. investment income, amortization of premium for fiscal 2015 was $1.11M, a 39.88% increase from fiscal 2014.
- ARROWHEAD PHARMACEUTICALS, INC. investment income, amortization of premium for fiscal 2014 was $793.89K, a 518.26% increase from fiscal 2013.
- ARROWHEAD PHARMACEUTICALS, INC. investment income, amortization of premium for fiscal 2013 was $128.41K.
| Period end | Investment Income, Amortization of Premium 3 month | Investment Income, Amortization of Premium 6 month | Investment Income, Amortization of Premium 9 month | Investment Income, Amortization of Premium 12 month |
|---|---|---|---|---|
| 2016-09-30 | $30.56K derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-14 | $52.44K derived: sum of 2 quarters · filed 2016-12-14 | $123.50K derived: sum of 3 quarters · filed 2016-12-14 | $231.90K 10-K · filed 2016-12-14 |
| 2016-06-30 | $21.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | $92.94K derived: sum of 2 quarters · filed 2016-08-09 | $201.35K 10-Q · filed 2016-08-09 | $366.76K derived: sum of 4 quarters · filed 2017-02-06 |
| 2016-03-31 | $71.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-10 | $179.46K 10-Q · filed 2016-05-10 | $344.87K derived: sum of 3 quarters · filed 2017-02-06 | $621.62K derived: sum of 4 quarters · filed 2017-02-06 |
| 2015-12-31 | $108.40K 10-Q · filed 2017-02-06 | $273.81K derived: sum of 2 quarters · filed 2017-02-06 | $550.56K derived: sum of 3 quarters · filed 2017-02-06 | $871.22K derived: sum of 4 quarters · filed 2017-02-06 |
| 2015-09-30 | $165.41K derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-14 | $442.16K derived: sum of 2 quarters · filed 2016-12-14 | $762.82K derived: sum of 3 quarters · filed 2016-12-14 | $1.11M 10-K · filed 2016-12-14 |
| 2015-06-30 | $276.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | $597.41K derived: sum of 2 quarters · filed 2016-08-09 | $945.11K 10-Q · filed 2016-08-09 | |
| 2015-03-31 | $320.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-10 | $668.36K 10-Q · filed 2016-05-10 | ||
| 2014-12-31 | $347.70K 10-Q · filed 2016-02-09 | |||
| 2014-09-30 | $793.89K 10-K · filed 2016-12-14 | |||
| 2013-09-30 | $128.41K 10-K · filed 2015-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |